Perspectives in diagnosis and management of malignant gliomas;Perspectives dans le diagnostic et la prise en charge des gliomes malins

Cancer/Radiotherapie

Volumn 12, Issue 6-7, 2008, Pages 695-700

  Psimaras, D ^a,b   Delattre, J Y ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Biomarkers; Etiology; Glioblastoma; Malignant glioma; Molecular based classification

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CARMUSTINE; IRINOTECAN; SOMATOMEDIN C; TEMOZOLOMIDE; TYROSINE KINASE RECEPTOR;

ANTIANGIOGENIC THERAPY; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CHROMOSOME TRANSLOCATION; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; ENVIRONMENTAL FACTOR; FOLLOW UP; GLIOBLASTOMA; HEREDITY; HUMAN; MORPHOMETRICS; NEUROIMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAIN NEOPLASMS; CELL CYCLE; FRANCE; GLIOMA; HUMANS; RADIOTHERAPY; SURVIVAL ANALYSIS; SURVIVORS;

EID: 55649107264     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2008.09.006     Document Type: Short Survey

References (21)

1. De Groot J.F., and Gilbert M.R. New molecular targets in malignant gliomas. Curr Op Neurol (2007) 712-718
2. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nature Med 2008; [published online Jul 31].
3. Eyler C.E., and Rich N.J. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 2839-2845
4. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 2683-2710
5. Gerstner E, Sorensen AG, Jain R, Batchelor T. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability and angiogenesis in gliomas. Curr Op Neurol 2008; sous presse.
6. Hormigo A., Gu B., Karimi S., Riedel E., Panageas K.S., Ma E., et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high grade gliomas. Clin Cancer Res 12 (2006) 5698-5704
7. Iafrate A.J., and Louis D.N. "MGMT for pt mgmt": is methylguanine-DNA methyltransferase testing ready for patient management?. J Mol Diagn (2008) 308-310
8. Kerbel R.S. Tumor Angiogenesis. N Engl J Med (2008) 2039-2049
9. Laprie A., Catalaa I., Cassol E., McKnight T.R., Berchery D., Marre D., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys (2008) 773-781
10. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 97-109
11. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan A., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 366-377
12. Malmer B., Adatto P., Armstrong G., Barnholtz-Sloan J., Bernstein J.L., Claus E., et al. Gliogene an international consortium to understand familial glioma. Cancer Epidemiol Biomarkers Prev (2007) 1730-1734
13. Martin-Duverneuil N., Guillevin R., and Chiras J. Imagerie des gliomes. Cancer Radiother (2008)
14. Mason W.P., and Cairncross J.G. Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology (2008) 365-373
15. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2006) 884
16. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating micro RNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA (2008) 10513-10518
17. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 3015-3024
18. Rodero M, Marie Y, Coudert M, Blondet E, Mokhtari K, Rousseau A, et al. A polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008; sous presse.
19. Stupp R., Mason W.P., Van Den Bent M.J., Weller M., Fisher B., Taphoorn J.B., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 987-996
20. Vredenburgh J.J., Desjardins A., Herndon II J.E., Marcello J., Reardon D.A., Quinn J.A., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 4722-4729
21. Wen P.Y., and Kesari S. Malignant gliomas in adults. N Engl J Med (2008) 492-507